Tag: companies

DAYTONA BEACH, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE: BRO) (“Brown & Brown” or the “Company”) today announced the pricing of its public offering of 39,215,686 shares of its common stock (the “common stock”), par value $0.10 per share, at a price to the public of $102.00 per share, for an aggregate offering amount of $4 billion. The offering is expected to close on June 12, 2025, subject to the satisfaction of customary closing conditions. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional $400 million in shares of common stock at the public offering price, less underwriting discounts.

NEW YORK CITY and NEW ORLEANS, June 10, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 4, 2025 to file lead plaintiff applications in a securities class action lawsuit against Reckitt Benckiser Group PLC (“Reckitt” or the “Company”) (OTC: RBGLY), if they purchased the Company’s American Depositary Shares (“ADSs”) between January 13, 2021 and July 28, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

NEW YORK and NEW ORLEANS, June 10, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Red Cat Holdings, Inc. (NasdaqCM: RCAT), if they purchased the Company’s securities between March 18, 2022 and January 15, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.

NEW YORK and NEW ORLEANS, June 10, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

NEW YORK CITY and NEW ORLEANS, June 10, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (NYSE: OGN), if they purchased the Company’s securities between October 31, 2024 and April 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.

NEW YORK and NEW ORLEANS, June 10, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against NET Power Inc. ("Net Power" or the "Company") (NYSE: NPWR), if they purchased the Company’s securities between June 9, 2023 and March 7, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Middle District of North Carolina.

NEW YORK CITY and NEW ORLEANS, June 10, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 8, 2025 to file lead plaintiff applications in a securities class action lawsuit against Compass Diversified Holdings (NYSE: CODI), if they purchased the Company’s securities between May 1, 2024 and May 7, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

BUENOS AIRES, June 10, 2025 (GLOBE NEWSWIRE) -- Grupo Financiero Galicia S.A. (Nasdaq: GGAL; Bolsas y Mercados Argentinos S.A./A3 Mercados S.A.: GGAL, the “Company”), one of Argentina’s largest financial services groups, announced today the pricing of the previously announced underwritten secondary offering (the “Offering”) by HSBC Bank plc (the “Selling Shareholder”) of 11,721,449 American Depositary Shares (“ADSs”) representing 117,214,490 Class B ordinary shares of the Company, par value Ps.1.00 per share (“Class B ordinary shares”) at a public offering price of $54.25 per ADS. The ADSs are not authorized for public offering in Argentina by the Argentine National Securities Exchange Commision (Comisión Nacional de Valores – “CNV”) and are not being offered or sold publicly under the Argentine Capital Markets Law No. 26,831, as amended and complemented.  The documents related to the Offering have not been filed with, reviewed or authorized by the CNV, and therefore the CNV has not made any determination as to the truthfulness or completeness of those documents.

WINNIPEG, Manitoba, June 10, 2025 (GLOBE NEWSWIRE) -- (TSX: NWC): The North West Company Inc. (the "Company" or "North West") today reported its unaudited financial results for the first quarter ended April 30, 2025. It also announced that the Board of Directors has declared a quarterly dividend of $0.40 to shareholders of record on June 27, 2025, to be paid on July 15, 2025.

EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced today that Quest was not informed or consulted, opposes and will not support the recently announced acquisition by privately held South Korea-based OQPBIOM Inc. (“OQM”) of a controlling interest in AdBioTech Co., Ltd. (“AdBioTech”), a public company listed on KOSDAQ in South Korea. OQM has announced that AdBioTech is the corporate vehicle through which it wishes to pursue the funding and advancement of its immunotherapy assets.